Development of a model for marburgvirus based on severe-combined immunodeficiency mice

Virology Journal

Volumn 4, Issue , 2007, Pages

  Warfield, Kelly L ^a   Alves, Derron A ^a   Bradfute, Steven B ^a   Reed, Daniel K ^a   VanTongeren, Sean ^a   Kalina, Warren V ^a   Olinger, Gene G ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GLUCOSE; MORPHOLINE DERIVATIVE; OLIGOMER; PHOSPHORUS DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA VIRUS; FEMALE; FILOVIRUS; GUINEA PIG; HEMORRHAGIC FEVER; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LETHALITY; LIVER HOMOGENATE; MALE; MARBURG VIRUS; MOUSE; NONHUMAN; PRIMATE; SCID MOUSE; SPLEEN; UREA NITROGEN BLOOD LEVEL; VIROGENESIS; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TITRATION; ANIMAL; IMMUNOLOGY; MOUSE MUTANT; PATHOGENICITY; PATHOPHYSIOLOGY; SEVERE COMBINED IMMUNODEFICIENCY; VIRUS HEMORRHAGIC FEVER;

CAVIA; MARBURGVIRUS; MUS; PRIMATES;

ANIMALS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, SCID; MODELS, ANIMAL; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 37549063070     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-108     Document Type: Article

References (41)

1. Hemorrhagic fever viruses as biological weapons: medical and public health management. L Borio T Inglesby CJ Peters AL Schmaljohn JM Hughes PB Jahrling T Ksiazek KM Johnson A Meyerhoff T O'Toole MS Ascher J Bartlett JG Breman EM Eitzen Jr. M Hamburg J Hauer DA Henderson RT Johnson G Kwik M Layton S Lillibridge GJ Nabel MT Osterholm TM Perl P Russell K Tonat, Jama 2002 287 18 2391 2405 10.1001/jama.287.18.2391 11988060
2. Defense against filoviruses used as biological weapons. M Bray, Antiviral Res 2003 57 1-2 53 60 10.1016/S0166-3542(02)00200-0 12615303
3. The evolving field of biodefence: Therapeutic developments and diagnostics. J Burnett EA Henchal A Schmaljohn S Bavari, Nat Rev Drug Disc 2005 4 281 297 10.1038/nrd1694
4. Are Hemorrhagic Fever Viruses Practical Aents for Biological Terrorism? C Peters, Emerg Infect 2000 4 201 209
5. Biosafety in Microbiological and Biomedical Laboratories. U.S. Dept. of Health and Human Services Centers for disease Control and Prevention National Institutes of Health, Richmond JY, McKinney RW, 5 2006
6. Category A agents. Centers for Disease Control and Prevention http://www.bt.cdc.gov/agent/agentlist.asp
7. Filovirus diseases. CJ Peters AS Khan, Curr Top Microbiol Immunol 1999 235 85 95 9893380
8. Marburg Agent Disease: In Man. GA Martini, Royal society of Tropical Medicine and Hygiene 1969 63 295 301 10.1016/0035-9203(69)90001-7
9. Isolation and identification of the "Marburg virus". R Siegert HL Shu W Slenczka, Dtsch Med Wochenschr 1968 93 12 604 612 4966285
10. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. JS Towner ML Khristova TK Sealy MJ Vincent BR Erickson DA Bawiec AL Hartman JA Comer SR Zaki U Stroher F Gomes da Silva F del Castillo PE Rollin TG Ksiazek ST Nichol, J Virol 2006 80 13 6497 6516 16775337 10.1128/JVI.00069-06
11. Risks and prevention of nosocomial transmission of rare zoonotic diseases. DJ Weber WA Rutala, Clin Infect Dis 2001 32 3 446 456 10.1086/318509 11170953
12. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. DG Bausch M Borchert T Grein C Roth R Swanepoel ML Libande A Talarmin E Bertherat JJ Muyembe-Tamfum B Tugume R Colebunders KM Konde P Pirad LL Olinda GR Rodier P Campbell O Tomori TG Ksiazek PE Rollin, Emerg Infect Dis 2003 9 12 1531 1537 14720391
13. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. N Jaax P Jahrling T Geisbert J Geisbert K Steele K McKee D Nagley E Johnson G Jaax C Peters, Lancet 1995 346 8991-8992 1669 1671 10.1016/S0140-6736(95)92841-3 8551825
14. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. M Bray K Davis T Geisbert C Schmaljohn J Huggins, J Infect Dis 1998 178 3 651 661 9728532
15. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. TR Gibb M Bray TW Geisbert KE Steele WM Kell KJ Davis NK Jaax, J Comp Pathol 2001 125 4 233 242 10.1053/jcpa.2001.0502 11798240
16. Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques: Evidence that Dendritic Cells Are Early and Sustained Targets of Infection. TW Geisbert LE Hensley T Larsen HA Young DS Reed JB Geisbert DP Scott E Kagan PB Jahrling KJ Davis, Am J Pathol 2003 163 6 2347 2370 14633608
17. Pathogenesis of Ebola Hemorrhagic Fever in Primate Models: Evidence that Hemorrhage Is Not a Direct Effect of Virus-Induced Cytolysis of Endothelial Cells. TW Geisbert HA Young PB Jahrling KJ Davis T Larsen E Kagan LE Hensley, Am J Pathol 2003 163 6 2371 2382 14633609
18. Vaccine research efforts for filoviruses. MK Hart, International Journal for Parasitology 2003 33 583 595 10.1016/S0020-7519(03)00064-X 12782057
19. Plaque assay for Ebola virus. JB Moe RD Lambert HW Lupton, J Clin Microbiol 1981 13 4 791 793 7014628
20. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. TW Geisbert LE Hensley PB Jahrling T Larsen JB Geisbert J Paragas HA Young TM Fredeking WE Rote GP Vlasuk, Lancet 2003 362 9400 1953 1958 10.1016/S0140-6736(03)15012-X 14683653
21. Gene-Specific Countermeasures Against Ebola Virus Based On Antisense Phosphorodiamidate Morpholino Oligomers. KL Warfield DL Swenson GG Olinger DK Nichols WD Pratt R Blouch DA Stein MJ Aman PL Iversen S Bavari, PLoS Pathogens 2006 2 1 16415982
22. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic Fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. TW Geisbert HA Young PB Jahrling KJ Davis E Kagan LE Hensley, J Infect Dis 2003 188 11 1618 1629 10.1086/379724 14639531
23. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. M Hevey D Negley J Geisbert P Jahrling A Schmaljohn, Virology 1997 239 1 206 216 10.1006/viro.1997.8883 9426460
24. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. PW Parren TW Geisbert T Maruyama PB Jahrling DR Burton, J Virol 2002 76 12 6408 6412 12021376 10.1128/JVI.76.12.6408-6412.2002
25. The role of the Type I interferon response in the resistance of mice to filovirus infection. M Bray, J Gen Virol 2001 82 Pt 6 1365 1373 11369881
26. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. SP Fisher-Hoch GS Platt G Lloyd DI Simpson GH Neild AJ Barrett, Lancet 1983 2 8358 1055 1058 10.1016/S0140- 6736(83)91041-3 6138602
27. Experimental infection of monkeys with the Marburg virus. R Haas G Maass, Marburg Virus New York, Springer-Verlag, Martini GA, Siegert R, 1971 136 143
28. Respiratory Marburg virus infection in guinea pigs. E Ryabchikova L Strelets L Kolesnikova O P'yankov A Sergeev, Arch Virol 1996 141 11 2177 2190 10.1007/BF01718224 8973532
29. Marburg agent disease. DI Simpson, Trans R Soc Trop Med Hyg 1969 63 303 309 10.1016/0035-9203(69)90002-9 4978540
30. Vervet Monkey Disease: Experimental infection of guinea pigs and monkeys with the causative agents. DI Simpson I Zlotnik DA Rutter, Br J Exp Pathol 1968 49 458 464 5727750
31. Pathophysiology of shock and haemorrhage in viral haemorrhagic fevers. S Fisher-Hoch, Southeast Asian J Trop Med Public Health 1987 18 3 390 391 3433168
32. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. M Bray S Hatfill L Hensley JW Huggins, J Comp Pathol 2001 125 4
33. Molecular characterization of guinea pig-adapted variants of Ebola virus. VE Volchkov AA Chepurnov VA Volchkova VA Ternovoj HD Klenk, Virology 2000 277 1 147 155 10.1006/viro.2000.0572 11062045
34. Molecular determinants of Ebola virus virulence in mice. H Ebihara A Takada D Kobasa S Jones G Neumann S Theriault M Bray H Feldmann Y Kawaoka, PLoS Pathog 2006 2 7 e73 16848640 10.1371/journal.ppat.0020073
35. Ebola virus: unravelling pathogenesis to combat a deadly disease. T Hoenen A Groseth D Falzarano H Feldmann, Trends Mol Med 2006 12 5 206 215 10.1016/j.molmed.2006.03.006 16616875
36. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. SP Reid LW Leung AL Hartman O Martinez ML Shaw C Carbonnelle VE Volchkov ST Nichol CF Basler, J Virol 2006 80 11 5156 5167 16698996 10.1128/JVI.02349-05
37. Interactions of Marburg virus nucleocapsid proteins. S Becker C Rinne U Hofsass HD Klenk E Muhlberger, Virology 1998 249 2 406 417 10.1006/viro.1998. 9328 9791031
38. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. CF Basler A Mikulasova L Martinez-Sobrido J Paragas E Muhlberger M Bray HD Klenk P Palese A Garcia-Sastre, J Virol 2003 77 14 7945 7956 12829834 10.1128/JVI.77.14.7945-7956.2003
39. The Ebola virus VP35 protein functions as a type I IFN antagonist. CF Basler X Wang E Muhlberger V Volchkov J Paragas HD Klenk A Garcia-Sastre P Palese, Proc Natl Acad Sci U S A 2000 97 22 12289 12294 11027311 10.1073/pnas.220398297
40. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. WB Cardenas YM Loo M Gale Jr. AL Hartman CR Kimberlin L Martinez-Sobrido EO Saphire CF Basler, J Virol 2006 80 11 5168 5178 16698997 10.1128/JVI.02199-05
41. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. Z Feng M Cerveny Z Yan B He, J Virol 2007 81 1 182 192 17065211 10.1128/JVI.01006-06